• 한국축산식품학회지
• /
• 제22권1호
• /
• pp.87-93
• /
• 2002

최근 고혈압을 예방하기 위한ACE 저해 펩타이드에 대한 연구는 주로 여러 가지 식품 단백질의 효소 가수분해물로부터 얻어진 펩타이드를 중심으로 이루어지고 있다. 본 연구에서는 케이신을 여러 가지 상업용 단백질분해 효소를 사용하여 ACE저해 효과가 높은 가수분해물 제조시 가수분해 조건이 ACE저해효과에 미치는 영향을 알아보자 하였으며 적정 가수분해 조건을 설정하고자 하였다. ACE 저해효과를 가지는 케이신 가수분해 물을 제조하기 위한 효소 종류, 첨가량 및 가수분해시간은 효소는 Aspergillus oryzae 유래의 promod 192를 사용하고, 효소의 첨가량은 케이신에 대하여 1%, 반응시간은 47$^{\circ}C$에서 12시간으로 하는 것이 적당하였다. 이 때 케이신 가수분해물의 $IC_{50}$/값은 248.71ug/m1(통상법), 265.84ug/ml(전처리법)로서 ACE 저해효과가 높았다.

• Tuberculosis and Respiratory Diseases
• /
• 제39권1호
• /
• pp.24-27
• /
• 1992

연구배경 : Angiotensin converting enzyme(ACE) 길항제인 Captopril용 최근 널리 쓰이는 혈압강하제로 바교적 부작용이 적은 것으로 알려져왔다. 그러나 1985년 Sesoko 등이 처음으로 Captopril에 의한 기침을 보고한 이래 관심이 높아져 최근 여러 예가 보고되고 있다. 방법 : 저자들은 최근 경험한 Captopril에 의한 기침환자 15명에 대한 임상상을 후향적으호 분석 하여 다음과 같은 결과를 얻었다. 결과 : 1) 대상 환자의 평균 연령은 58.5세 였으며, 남자 5예, 여자 10예 였다. 2) 대상 환자의 질환은 고혈압이 13예, 울혈성 심부전이 2예 였으며 과거력상 흡연력이 있었던 경우가 3예였다. 3) 대상 환자의 Captopril 하루 평균 사용량은 43.3mg 이었고, 사용기간은 5일에서 180일 까지 다양하였다. 4) Captopril에 의한 기침으로 판명되기 까지의 기침의 기간은 평균 47.5일 이었고, Captopril 사용 중지 후 기침이 소실될때 까지의 기간은 1~7일 이었다. 결론 : Captopril을 사용하고 있는 환자에서 원인없이 기침이 발생하였을 때는 Captopril에 의한 기침을 강력히 의심해야 한다.

• 미생물학회지
• /
• 제45권1호
• /
• pp.54-57
• /
• 2009

대두발효식품인 청국장에는 다양한 항산화물질, peptide 등의 생리활성물질이 존재한다. 청국장 ethanol 추출물은 285 nm에서 0.55의 흡광도 값을 보여 주었다. 이 영역에는 phenol을 포함한 아미노산 및 peptide류가 포함되어 있다고 알려져 있다. 1,1-diphenyl-2-picrylhydrazyl (DPPH)방법으로 청국장의 항산화도를 측정했을 때, ethanol 추출물의 농도가 증가할수록 항산화도는 증가하였다. 무염 생청국장 30 g을 복용하고 2시간 마다 혈압을 측정하였다. 수축기혈압은 복용 후 6시간 지난 후, 평균혈압이 14 mmHg 떨어졌고, 이완기혈압은 8 mmHg 떨어지는 등 혈압강하 효과가 뚜렷하였다. 청국장에 존재하는 daidzein, 항산화물질, Lys-Pro과 같은 angiotensin I-converting enzyme (ACE) 억제제 등이 복합적으로 작용하면서 혈압강하에 기여할 수 있을 것이다.

• Journal of Veterinary Science
• /
• 제24권2호
• /
• pp.26.1-26.11
• /
• 2023

Background: Angiotensin-converting enzyme inhibitor (ACEi) inhibits the catalysis of angiotensin I to angiotensin II and the degradation of substance P (SP) and bradykinin (BK). While the possible relationship between ACEi and SP in nociceptive mice was recently suggested, the effect of ACEi on signal transduction in astrocytes remains unclear. Objectives: This study examined whether ACE inhibition with captopril or enalapril modulates the levels of SP and BK in primary cultured astrocytes and whether this change modulates PKC isoforms (PKCα, PKCβI, and PKCε) expression in cultured astrocytes. Methods: Immunocytochemistry and Western blot analysis were performed to examine the changes in the levels of SP and BK and the expression of the PKC isoforms in primary cultured astrocytes, respectively. Results: The treatment of captopril or enalapril increased the immunoreactivity of SP and BK significantly in glial fibrillary acidic protein-positive cultured astrocytes. These increases were suppressed by a pretreatment with an angiotensin-converting enzyme. In addition, treatment with captopril increased the expression of the PKCβI isoform in cultured astrocytes, while there were no changes in the expression of the PKCα and PKCε isoforms after the captopril treatment. The captopril-induced increased expression of the PKCβI isoform was inhibited by a pretreatment with the neurokinin-1 receptor antagonist, L-733,060, the BK B1 receptor antagonist, R 715, or the BK B₂ receptor antagonist, HOE 140. Conclusions: These results suggest that ACE inhibition with captopril or enalapril increases the levels of SP and BK in cultured astrocytes and that the activation of SP and BK receptors mediates the captopril-induced increase in the expression of the PKCβI isoform.

• Archives of Pharmacal Research
• /
• 제21권2호
• /
• pp.168-173
• /
• 1998

The epoxyalkanoyl derivatives were designed and synthesized as ACE inhibitors. Coupling of unsaturated carboxylic acids with amino acids and following epoxidation with dimethyldioxirane gave the epoxyalkanoyls with high yield. The inhibitory activity of synthesized compounds on angiotensin converting enzyme was $IC_{50}$ values of 0.06~5.5 ${\mu}M$.

• Journal of Microbiology and Biotechnology
• /
• 제12권1호
• /
• pp.59-64
• /
• 2002

An angiotensin I-converting enzyme (EC 3.4.15.1) (ACE), which can convert inactive angiotensin I into angiotensin II, a vasoconstrictor, is one of the key enzymes in controlling hypertension. It is suggested that the inhibition of ACE prevents hypertension, and many inhibitory peptides have already been reported. In the current study, oligonucleotides encoding ACE inhibitory peptides (IY, VKY) were chemically synthesized and designed to be multimerised due to isoschizomer sites (BamHI, BglII). The cloned gene named AP3 was multimerised up to 6 times in pBluescript and expressed in BL2l containing pGEX-KG. The fusion protein (GST-AP3) was easily purified with a high recovery by an affinity resin, yielding 38 mg of synthetic AP3 from a 1-1 culture. The digestion of AP3 by chymotrypsin exhibited an $IC_50$ value of $18.53{\mu}M$. In conclusion, the present experiment indicated that AP3 could be used as a dietary antihypertensive drug, since the potent ACE inhibitory activity of AP3 could be activated by chymotrypsin in human intestine.

• 한국생물공학회:학술대회논문집
• /
• 한국생물공학회 2003년도 생물공학의 동향(XII)
• /
• pp.498-498
• /
• 2003

• 한국영양학회:학술대회논문집
• /
• 한국영양학회 2003년도 연합학술대회
• /
• pp.198.1-198.1
• /
• 2003

• 대한약학회:학술대회논문집
• /
• 대한약학회 2003년도 Proceedings of the Convention of the Pharmaceutical Society of Korea Vol.2-2
• /
• pp.250.1-250.1
• /
• 2003

Background Aldosterone has an important role in the pathophysiology of heart failure. Aldosterone promotes the retention of sodium, the loss of magnesium and potassium, sympathetic activation, parasympathetic inhibition, myocardial and vascular fibrosis, baroreceptor dysfunction, and vascular damage and impairs arterial compliance. Objectives We investigated the effects of additional spironolactone to angiotensin-converting enzyme inhibitor (ACEI) / angiotensin-II receptor blocker (ARB) in patients with heart failure. (omitted)

• Asian-Australasian Journal of Animal Sciences
• /
• 제21권5호
• /
• pp.732-737
• /
• 2008

This study developed a natural ingredient as a functional food possessing properties of attenuation of hypertension and cardiovascular hypertrophy. In a previous study hydrolysates obtained from chicken leg bone protein using Alcalase strongly inhibited angiotensin I converting enzyme (ACE) in vitro. In particular, hydrolysate (A4H) from four hours of incubation exhibited the highest ACE inhibitory activity (IC50 = 0.545 mg/ml). A4H was selected as a potent ACE inhibitor and orally administrated to spontaneously hypertensive rats (SHR) for eight weeks to investigate attenuating effects on age-related development of hypertension and cardiovascular hypertrophy. Results showed that treatment with A4H of SHRs attenuated the development of hypertension as effectively as the clinical antihypertensive drug captopril. Moreover, a significantly lower heart to body weight ratio and thinness of coronary arterial wall was observed in SHRs that had been treated with A4H or captopril. The results suggest that A4H can be utilized in developing an ACE inhibitor as a potential ingredient of functional foods to alleviate hypertension and cardiovascular hypertrophy.